Santen Pharmaceutical Co Ltd
TSE:4536
Santen Pharmaceutical Co Ltd
Income from Continuing Operations
Santen Pharmaceutical Co Ltd
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Santen Pharmaceutical Co Ltd
TSE:4536
|
Income from Continuing Operations
¥26.7B
|
CAGR 3-Years
43%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Income from Continuing Operations
¥144.2B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Income from Continuing Operations
¥201B
|
CAGR 3-Years
39%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Income from Continuing Operations
¥141.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-1%
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Income from Continuing Operations
¥326.4B
|
CAGR 3-Years
16%
|
CAGR 5-Years
27%
|
CAGR 10-Years
18%
|
|
Astellas Pharma Inc
TSE:4503
|
Income from Continuing Operations
¥17B
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-15%
|
See Also
What is Santen Pharmaceutical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
26.7B
JPY
Based on the financial report for Mar 31, 2024, Santen Pharmaceutical Co Ltd's Income from Continuing Operations amounts to 26.7B JPY.
What is Santen Pharmaceutical Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
3%
The average annual Income from Continuing Operations growth rates for Santen Pharmaceutical Co Ltd have been 43% over the past three years , -4% over the past five years , and 3% over the past ten years .